CTOs on the Move


 
EGEN is a Huntsville, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.egeninc.com
  • 601 Genome Way Ste 3100
    Huntsville, AL USA 35806
  • Phone: 256.512.0077

Executives

Name Title Contact Details

Similar Companies

Sojournix

Sojournix is a clinical stage pharmaceutical company focused on creating new medicines to improve the treatment of women’s health and neuroendocrine disorders.

BioSeek

BioSeek is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Midwest AgEnergy Group

Midwest AgEnergy Group is a North Dakota biofuels enterprise. Midwest AgEnergy Group owns Blue Flint Ethanol, a 65 million gallon per year biorefinery in operation since 2007 near Underwood, N.D., and Dakota Spirit AgEnergy, a 65 million gallon per year biorefinery east of Jamestown, ND that began production in June 2015. Together with our partners, we are building a renewable energy future for the country, increasing demand for North Dakota farmers, and bringing prosperity to our communities.

Syndax

Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC). Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body`s immune response to tumors. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck and Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Merck KGaA, Darmstadt, Germany and Pfizer Inc. in ovarian cancer. Syndax is also developing entinostat as a combination therapeutic in a Phase 3 clinical trial that is being conducted with ECOG-ACRIN for advanced hormone receptor positive breast cancer.

Palleon Pharmaceuticals

Palleon is targeting glycan-sensing checkpoints to unleash both the innate and adaptive immune responses to cancer.